118 citations
,
November 2024 in “World Journal of Biology Pharmacy and Health Sciences” This study highlights that the ACIP strongly recommends COVID-19 vaccination and booster doses for pregnant women, those breastfeeding, or trying to conceive, due to the safety of non-live vaccines in these groups and the protection they also offer to infants.
9 citations
,
November 2020 in “Medical Hypotheses” Hair loss may link to weaker COVID-19 immunity, suggesting possible need for extra vaccine boost.
8 citations
,
July 2024 in “European journal of medical research” This study reported that alopecia areata following COVID-19 vaccination is rare, occurring mostly after the first dose and associated with several vaccine types, particularly Pfizer.
3 citations
,
January 2023 in “Skin appendage disorders” This study reported five cases of alopecia areata following COVID-19 vaccination, with one patient experiencing worsening symptoms with each vaccine booster.
2 citations
,
February 2023 in “Vaccines” This study reported cases of post-vaccine telogen effluvium and alopecia among five individuals in Ecuador following a mixed COVID-19 vaccination regimen, typically appearing within 3 to 17 days after inoculation.
1 citations
,
October 2022 in “Current Dermatology Reports” This review discusses various skin reactions after SARS-CoV-2 infection and COVID-19 vaccination, noting a higher incidence with mRNA vaccines than adenovirus vector vaccines, and reports no new clinical results.
1 citations
,
January 2023 in “IDCases” This case study describes a rare instance of alopecia universalis in a Japanese patient following an mRNA COVID-19 vaccination.
September 2023 in “Journal of the American Academy of Dermatology” The document concludes that more research is needed to confirm if COVID-19 vaccines cause a type of hair loss called alopecia areata.
January 2025 in “Consultant” In this case report, a 56-year-old Black man experienced patchy scalp hair loss which began four months after his second COVID-19 vaccination, also considering his medical history of hypertension and type 2 diabetes.
28 citations
,
September 2021 in “JAAD Case Reports” This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.
12 citations
,
December 2021 in “Frontiers in Medicine” This study observed that dermatological patients using certain immunosuppressants, like azathioprine and high-dose prednisolone, had a reduced humoral immune response to the Sinovac-CoronaVac COVID-19 vaccine compared to those without such treatments.
April 2026 in “Portuguese Journal of Dermatology and Venereology” This review summarizes the various skin manifestations linked to COVID-19 infection, vaccination, and personal protective equipment, highlighting their clinical importance and discussing psychological stress and social isolation as additional dermatologic factors.
3 citations
,
January 2023 in “Indian Dermatology Online Journal” This study reported a series of mild to moderate cutaneous adverse drug reactions following COVID-19 vaccination, predominantly after Covishield, with only one requiring hospitalization.
46 citations
,
September 2022 in “International Journal of Environmental Research and Public Health” This study found that COVID-19 vaccine booster dose acceptance was high in the East Mediterranean Region, especially among those informed by the Ministry of Health, but concerns about benefits and side effects influenced rejection.
5 citations
,
January 2022 in “Journal of the European Academy of Dermatology and Venereology” In this study, Covishield vaccination was associated with cutaneous adverse effects, notably telogen effluvium and urticaria, among recipients at a hospital in northern India.
November 2023 in “Advances in clinical medical research & healthcare delivery” September 2023 in “Indian Journal of Postgraduate Dermatology” In this study, 2% of healthcare workers vaccinated with Covaxin or Covishield reported new skin reactions, with a slightly higher incidence following Covaxin; significant differences were observed among paramedical staff.
15 citations
,
January 2022 in “Journal of Infection” This study's meta-analysis found that COVID-19 vaccines are effective and safe for children, with inactivated vaccines showing the highest effectiveness and causing less injection site pain compared to attenuated vaccines.
January 2023 in “Yādgār.” This study found a significant relationship between COVID-19 vaccine injections and the occurrence of abnormal uterine bleeding, suggesting the need for more research on the vaccines' reproductive health effects.
April 2021 in “Journal of Investigative Dermatology” This study found that multicomponent microarray patches for SARS-CoV-2 vaccination produced stronger immune responses and fewer side effects in mice compared to traditional intramuscular injection.
16 citations
,
March 2022 in “Journal of Infection” This study observed that sera from Covaxin-vaccinated individuals showed reduced neutralization ability against the Omicron variant compared to B.1, Beta, and Delta variants, with breakthrough infections boosting immune response more effectively than vaccination alone.
9 citations
,
January 2023 in “Journal of Cutaneous Immunology and Allergy” This case report describes a 37-year-old woman who developed widespread hair loss following the BNT162b2 mRNA vaccine, which mostly recovered after topical corticosteroid treatment.
2 citations
,
October 2022 in “Current Dermatology Reports” This review discusses the impact of immune-modifying therapies on COVID-19 vaccine responses, noting that a complete vaccine course can improve initially inadequate humoral responses among treated individuals compared to a single dose.
May 2023 in “Dermatology Reports” In this original study, researchers documented 121 COVID-19 cases with a wide range of mucocutaneous manifestations, some linked to internal organ damage and others to new vaccine-associated dermatoses, emphasizing the importance of rapid diagnosis to prevent potentially life-threatening systemic events.
16 citations
,
December 2021 in “Frontiers in Endocrinology” This review discusses the role of sex hormones in COVID-19 severity and reports no new clinical results; the authors suggest further research for gender-based personalized treatment options.
6 citations
,
September 2022 in “Vaccines” This study described cases of alopecia areata occurring after COVID-19 vaccination and highlights management using both topical and systemic therapies.
2 citations
,
August 2022 in “JAAD case reports” This review discusses vaccine safety concerns for individuals with autoimmune and inflammatory conditions, noting vaccine hesitancy due to observed exacerbations post-vaccination and a lack of comprehensive trial data.
2 citations
,
October 2023 in “The American journal of case reports” This report observed a case of pilomatrixoma appearing at the COVID-19 vaccination site of a 65-year-old man, aligning with previous findings that suggest a potential association between vaccination sites and this benign tumor.
December 2024 in “Archives of Dermatological Research” The authors concluded that there is no increased association between COVID-19 vaccination and alopecia areata, and the overall incidence of the condition in vaccinated individuals matches historical controls.
May 2023 in “British Journal of Dermatology” COVID-19 can cause long-term skin problems and has changed how skin doctors work.